APVO - Aptevo Therapeutics Inc
Aptevo Therapeutics Inc Logo

APVO - Aptevo Therapeutics Inc

https://aptevotherapeutics.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Aptevo Therapeutics ( NASDAQ:APVO ) , AIRO Group Holdings ( NASDAQ:AIRO )
Benzinga • 2 months, 3 weeks ago • score: -0.06
U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday. Shares of Smith & Wesson Brands Inc SWBI fell sharply in pre-market trading after the company reported worse-than-expected fourth-quarter EPS and sales.
Neutral
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment - Aptevo Therapeutics ( NASDAQ:APVO )
Benzinga • 5 months, 3 weeks ago • score: 0.15
90% of frontline AML patients achieved remission with mipletamig plus ven/aza, surpassing the 66% rate seen with ven/aza alone. No cytokine release syndrome ( CRS ) has been reported in the RAINIER trial, reinforcing the therapy's safety profile. Pelosi's latest AI pick skyrocketed 169% in ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.

52W High
$381.10
52W Low
$1.54
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
5.77
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
0.00
Forward P/E (<15 better)
3.95
EV/EBITDA (<8 favorable)
0.39
EV/Revenue (<3 favorable)
0.12
P/S (TTM) (<3 favorable)
1.61
P/B (<3 favorable)
0.81
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
0.48%
Shares Outstanding
3,287,900
Float
3,287,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
291,000
EPS (TTM)
2680.54
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-4.37%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentum
Value
-0.3129
Previous
-0.3218
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025